Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. https://www.fda.gov/regulatory-information/ search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations- eligibility-criteria-enrollment-practices-and-trial (2020).
2. Van Spall, H. G., Toren, A., Kiss, A. & Fowler, R. A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. J. Am. Med. Assoc. 297, 1233–1240 (2007).
3. Fehrenbacher, L., Ackerson, L. & Somkin, C. Randomized clinical trial eligibility rates for chemotherapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 27, 6538 (2009).
4. Huang, G. D. et al. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. Contemp. Clin. Trials 66, 74–79 (2018).
5. National Cancer Institute. Report of the National Cancer Institute Clinical Trials Program Review Group. http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/bsactprgmin.pdf (2017).
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献